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ABSTRACT 
INTRODUCTION: Hyperactivity of the Hypothalamic-Pituitary-Adrenal (HPA) axis and high cortisol 
levels have been widely reported in patients with mood disorders but previous clinical trials 
investigating the efficacy of antiglucocorticoid treatment in this population have reported inconsistent 
findings. These inconsistencies among these studies may be because not all patients with mood 
disorders have increased HPA axis activity and therefore might not benefit from antiglucocorticoid 
treatment. The aim of this meta-analysis was to investigate whether baseline cortisol levels influence 
influence the efficacy of antiglucocorticoid drugs in patients with mood disorders. 
METHODS: PubMed and Scopus databases were searched systematically up to October 2018. We 
included studies using metyrapone, ketoconazole or mifepristone in patients with major depressive 
disorder, bipolar disorder and major depressive disorder with psychotic symptoms. We tested for a 
difference in cortisol levels between responders (a reduction equal to or greater than 30% on depression 
scales following antiglucocorticoid treatment) and non-responders (a reduction of less than 30% on 
depression scales). We performed a meta-analysis to look specifically at differences in cortisol levels 
in the sample of patients treated with cortisol synthesis inhibitors (metyrapone and ketoconazole) and 
in those treated with glucocorticoid receptor (GR) antagonist (mifepristone). 
RESULTS: We were able to retrieve data from 11 of the 16 selected studies and to include 9 studies in 
the meta-analysis. In the overall sample (N=846), responders had similar baseline cortisol levels 
compared with non-responders (standardised mean difference, SMD = -0.03, 95% CI [-0.17, 0.12], p= 
0.75). In the group of patients treated with cortisol synthesis inhibitors, responders (N= 109) had 
significantly higher peripheral baseline cortisol levels compared with non-responders (SMD= 0.42, 
95% CI [0.01, 0.83], p= 0.047). In the group of patients treated with a GR antagonist (N= 737), both 
responders and non-responders had similar baseline cortisol levels (SMD= -0.09, 95% CI [-0.25, 
0.07], p= 0.26). 
CONCLUSION: Our data suggest that only patients with higher cortisol levels at baseline benefit from 
treatment with cortisol synthesis inhibitors and support a potential role for cortisol as a predictive 
biomarker for treatment with cortisol synthesis inhibitors in patients with mood disorders. 
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1. INTRODUCTION 
Given the strong evidence of hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in patients 
with mood disorders, several previous studies have investigated the efficacy of antiglucocorticoid 
treatment in this population (Maric and Adzic, 2013). However, the results of these studies investigating 
the efficacy of antiglucocorticoid treatments in mood disorders are inconsistent. The only extant 
Cochrane review focused mainly on the efficacy of mifepristone treatment in patients with psychosis 
(Garner et al., 2016). Therefore, this meta-analysis aimed to clarify possible reasons behind the 
inconsistencies of the findings reported so far. 
Mood disorders are the second leading cause of disability worldwide and available treatments are not 
always effective (Nemeroff and Owens, 2002). It has been widely acknowledged that some patients 
with depression show a hyperactivation of the HPA axis (Papiol et al., 2007). Between 40% and 60% 
of depressed patients with mood disorders show high levels of circulating cortisol or other 
dysregulations of the HPA axis (Keller et al., 2017), with rates varying according to specific diagnoses. 
Specifically, dexamethasone test (DST) non-suppression has been reported in major depressive disorder 
(MDD) (up to 43%), major depressive disorder with psychotic symptoms (PMD) (up to 67%), bipolar 
disorder manic episode (up to 41%) and bipolar disorder mixed episode (up to 78%), (Arana and 
Mossman, 1988). 
Hypercortisolemia may play a role in the development of treatment-resistant depression (TRD) (Juruena 
et al., 2013). About 30% of patients with MDD do not respond to current antidepressant treatments, 
which mainly target monoamine transporters (Ionescu et al., 2015). The underlying mechanism may 
involve the negative effects of an excess of glucocorticoids on neuroplasticity and/or the modulation of 
neurotransmission. Notably, the hyperproduction of glucocorticoids (GC) decreases levels of serotonin 
and norepinephrine available in the synaptic cleft (Zhang et al., 2018). As a result of this evidence, 
several studies have tested the efficacy of antiglucocorticoids in subjects with mood disorders (Reus 
and Wolkowitz, 2001).  
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Antiglucocorticoid medications decrease the levels of glucocorticoid hormones (such as cortisol) either 
through inhibition of cortisol synthesis or through the antagonism of glucocorticoid receptors (GRs) 
(Price et al., 1996). The efficacy of the antiglucocorticoid treatment as an add-on treatment in depression 
still remains unclear and under investigation. 
There are many methodological differences among trials, (e.g. dose of administration and the subtype 
of the mood disorder), which make it difficult to reach clear conclusions. Another important factor 
which may explain the inconsistency across the literature regards the baseline cortisol levels of the 
patients treated, as not all patients are hypercortisolemic. A parallel may be studies investigating anti-
inflammatory drugs in patients with depression, which suggest that it is mainly subjects with high levels 
of inflammation who show a better response to anti-inflammatory treatment (Raison et al., 2013). 
Similarly, it is plausible that only patients with higher levels of cortisol will show a response 
to antiglucocorticoids.  
The aim of this meta-analysis was to investigate the possible association between baseline cortisol 
levels and the efficacy of antiglucocorticoid treatment in patients with mood disorders. We considered 
as baseline the cortisol levels prior to each antiglucocorticoid treatment and/or prior to the effect of any 
stimulation (e.g. dexamethasone). We hypothesized that patients with mood disorders who respond 
to antiglucocorticoid treatment would have higher baseline levels of cortisol compared with patients 
not responding to antiglucocorticoid treatment. A secondary aim of the meta-analysis was to test 
whether baseline cortisol levels predict the response to antiglucocorticoid treatment differently based 
on the mechanism of action of the drug (cortisol inhibitors vs glucocorticoid receptor antagonist). 
 
2. METHODS 
We searched the literature published until October 2018 in PubMed and Scopus databases using the 
following search words and synonyms: (“mood disorders”  OR “depression” OR “major depressive 
disorder” OR “major depressive disorder with psychotic symptoms” OR “bipolar disorder” OR 
“depressive symptoms” OR “treatment-resistant depression”) AND (“antiglucocorticoid” OR 
“glucocorticoid antagonist” OR “cortisol antagonist” OR “ketoconazole” OR “mifepristone” OR “RU-
486” OR “metyrapone”) AND (“cortisol” OR “hypothalamic-pituitary-adrenal axis” OR “HPA” OR 
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“hyperactivity”). Articles were limited to research published in English language. One author screened 
the abstracts for eligibility (LG) and three authors (LG, MV and ED) assessed the articles for relevance. 
 
2.1 Eligibility of the studies: inclusion and exclusion criteria  
Inclusion Criteria: 1) mood disorders: major depressive disorder (MDD), major depressive disorder 
with psychotic symptoms (PMD), bipolar disorder (BD), 2) biomarker: cortisol; 3) clinical scales: 
Hamilton Rating Scale for Depression (HDRS, HRS, HAMD), Montgomery–Åsberg Depression 
Rating Scale (MADRS); 4) type of study design: placebo-controlled trial, clinical trial randomized, 
double-blind, single-blind, pilot study, crossover study, open-label; 5) antiglucocorticoids: 
ketoconazole, metyrapone, mifepristone. 
Exclusion Criteria: 1) comorbidity with other psychiatric disorders or with other medical conditions; 
2) lack of cortisol measurement; 3) lack of clinical outcome assessment; 4) series case studies and case 
reports; 5) studies investigating the effects of antiglucocorticoids which did not fit in the categories of 
cortisol inhibitors or GR antagonist, (this was done to reduce heterogeneity of mechanism of action). 
In order to avoid the effect of the cortisol circadian rhythm, we included in the analyses afternoon and 
evening cortisol values when possible.  
  
2.2 Studies overview 
The initial search produced 436 results on Pubmed and 1201 results on Scopus. We selected 16 studies 
and we were able to retrieve data from a total of 11 studies. From the 16 studies, 3 were excluded as 
they were reporting data from overlapping samples with studies included (Raven et al., 1996; Gallagher 
et al., 2008; Block et al., 2017). From the 13 remaining studies, we  were able to retrieve data from a 
total of 11 (Belanoff et al., 2002; Block et al., 2018; Flores et al., 2006; Jahn et al., 2004; McAllister-
Williams et al., 2016; O’Dwyer et al., 1995; Paslakis et al., 2011; Thakore and Dinan, 1995; Watson et 
al., 2012; Wolkowitz et al., 1999; Young et al., 2004) and we were able to include 9 of these 11 studies 
in the meta-analysis (Belanoff et al., 2002; Block et al., 2018; Flores et al., 2006; Jahn et al., 2004; 
McAllister-Williams et al., 2016; O’Dwyer et al., 1995; Watson et al., 2012; Wolkowitz et al., 1999; 
Young et al., 2004). A description of the 13 studies is summarised in table 1. 
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In the meta-analysis, we included only 9 of the 11 studies, because we found in the study by Paslakis 
et al (2011) only one responder in a sample of 6 treated subjects and we did not find non-responders in 
the study by Thakore and Dinan (1995). The 9 analysed studies comprised a total of 846 subjects. 
The period of drug administration varied from a minimum of 7 days to a maximum of 4 weeks. Studies 
investigating “ketoconazole” and “metyrapone” were mainly conducted in patients with MDD, whilst 
the majority of studies investigating “mifepristone” were conducted in BD and PMD patients. Among 
the selected articles, there was no study using mifepristone treatment in MDD patients or testing 
ketoconazole or metyrapone in PMD patients. See table 1. 
 
3. ANALYSIS 
3.1 Data extraction 
For each study, we considered subjects treated with antiglucocorticoid treatment and did not consider 
the placebo group. We defined as responders (R) as depressed patients with a reduction equal to or 
greater than 30% on depression scales and as non-responders (NR) as those with a reduction less than 
30% on depression scales. In the selected studies, the clinical scales investigating depressive outcome 
were: Hamilton Rating Scale for Depression (HDRS; HRS; HAMD) and the Montgomery–Åsberg 
Depression Rating Scale (MADRS). 
From the included studies, we extracted information on: a) population (number of participants, number 
of responders and non-responders to antiglucocorticoid treatment, number of patients with MDD, PMD 
or BD); b) severity of depression (mean and SD of depression scale scores divided into responders and 
non-responders); c) type of antiglucocorticoid treatment; d) peripheral baseline cortisol levels (divided 
into responders and non-responders). 




3.2 Statistical analysis  
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We extracted data on the mean and standard deviation (SD) of peripheral baseline cortisol levels in 
responders and non-responders to antiglucocorticoid treatment. When needed, we calculated mean and 
SD from median and range/standard error of the mean of cortisol levels. We calculated Standardized 
Mean Difference(SMD), 95% confidence interval (CI), test for overall effect (Z). We assessed the 
heterogeneity using χ 2 test and I2-index. A high level of heterogeneity was considered when the p-value 
of the χ 2-test was below 0.05 and I2-index was more than 50%. 
We first analysed differences in baseline cortisol levels in responders and non-responders to 
antiglucocorticoid treatments in all studies. We then conducted separate analyses based on the 
mechanism of action of the antiglucocorticoid treatment, by testing differences in 1) baseline cortisol 
levels in responders and non-responders to synthesis cortisol inhibitors (metyrapone, ketoconazole) in 
patients with MDD; and 2) baseline cortisol levels in responders and non-responders to GR antagonist 
(mifepristone) in patients with PMD and BD. Statistical analyses were performed with Statistic and 




4.1 Baseline cortisol levels do not predict response to antiglucocorticoid treatment in patients with 
mood disorders 
In the total number of subjects considered for the meta-analysis (N= 846), responders (N=555) have 
similar baseline cortisol levels compared with non-responders (N= 291), (Standardized Mean 
Difference (SMD) = -0.025, 95% Ci [-0.173, 0.124], p= 0.747). The heterogeneity is low (2  = 23.00, 
p value of 2  =0.084, I2 = 34.8 %), see figure 2. 
 
4.2 Higher baseline cortisol levels predict response to cortisol synthesis inhibitors (metyrapone, 
ketoconazole)  
In the group of patients treated with cortisol synthesis inhibitors (metyrapone, ketoconazole) (N= 109), 
responders (N= 53) have significantly higher peripheral baseline cortisol levels compared with non-
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responders (N= 56). (SMD=0.421, 95% CI [0.010, 0.833], p= 0.045). The heterogeneity is low (2  = 
4.35, p value of 2  =0.226, I2 = 31.1 %), see figure 3. The studies focussing on cortisol synthesis 
inhibitors were all investigating patients with MDD and did not include patients with PMD and BD. 
 
4.3 Baseline cortisol levels do not predict response to glucocorticoid receptor antagonist 
(mifepristone) 
In the group of patients treated with glucocorticoid receptor antagonist (mifepristone) (N=737), 
responders (N=502) and non-responders (N=235) have similar levels of baseline cortisol. (SMD= -
0.092, 95% CI [-0.251, 0.068], p= 0.261).  
The heterogeneity is low (2 = 13.47, p value of 2 =0.264, I2= 18.3%), see figure 4. The studies 
focussing on glucocorticoid receptor antagonists were all investigating patients with BPMD and BD 
and did not include patients with MDD. 
 
4.4 Cortisol levels after treatment do not significantly differ between responders and non-
responders 
In order to explore the difference in cortisol levels after treatment between responders and non-
responders, a series of independent sample T-tests have been run to compare cortisol means when data 
after treatment were available. Only one study (Wolkowitz et al., 1999) showed a significant difference 
(p= 0.032) between responders (N= 4) and non-responders (N=5) with non-responders having lower 
cortisol levels at follow-up compared with responders. In the other studies, we did not find significant 
difference between groups after administration of antiglucocorticoid treatments. 
 
8. DISCUSSION 
Our findings did not show a significant difference in baseline cortisol levels in patients responding 
to antiglucocorticoid treatments when compared with patients not responding to these medications in 
the overall sample. However, this result changes when we run further analyses taking into account the 
specific mechanism of action of the drugs. In particular, we found significantly higher baseline cortisol 
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levels in patients responding to cortisol synthesis inhibitors compared with non-responders (all studies 
were in major depressive disorder patients), while we found similar baseline cortisol levels in patients 
responding or not to GR antagonist (all studies were in major depressive disorder with psychotic 
symptoms and bipolar disorder depressed patients). 
The differences we detected between the group treated with cortisol inhibitors and those treated with a 
GR antagonist may be related to the differences in the pharmacological actions of 
these antiglucocorticoid drugs.  Ketoconazole and metyrapone decrease cortisol levels by acting in the 
first and final steps of cortisol production, respectively (Becker 2001; Sampath-Kumar et al., 1997; 
Sonino, 1987), whereas mifepristone firstly increases cortisol levels by acting on HPA axis feedback 
mechanism (Kling et al., 2009) and also has an effect on the progesterone receptor. Specifically, 
Gallagher and colleagues found an increase of cortisol levels at day 7 after the mifepristone 
administration at the baseline and a significant decrease from day 7 to day 21 in patients with bipolar 
disorder and in patients with schizophrenia (Gallagher et al., 2008). These differences in 
pharmacodynamic could lead to a different effect on mineralocorticoid receptors (MRs)/GRs’ balance. 
MRs and GRs have different affinities for cortisol. Specifically, MRs have a high affinity for this 
hormone and are activated by low cortisol levels, while GRs have a low affinity for this hormone 
and are activated only in presence of high cortisol levels (Joëls and de Kloet (1994); Kalman and 
Spencer (2002); Reul and de Kloet (1985)). Consequentially, administration of cortisol synthesis 
inhibitors in patients with high baseline cortisol levels may up-regulate MRs by lowering the levels of 
the steroid hormone (Jahn et al., 2004). However, mifepristone administration temporarily leads to a 
further increase of cortisol levels (Yuen et al., 2017) which may not help to reset the MRs/GRs balance 
in patients with already high cortisol levels. 
However, the differences we found between the two classes of antiglucocorticoid treatments could 
also be explained by the differences between the populations studied. In fact, studies which used 
cortisol synthesis inhibitors focused on MDD patients, whereas those using the GR antagonist focused 
on PMD and BD patients. Previous studies suggested different patterns of HPA axis dysregulation 
between mood disorders and more specifically, between major depressive disorder with psychotic 
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symptoms and nonpsychotic major depression populations (Keller et al., 2006) that could partly account 
for a different response to antiglucocorticoid treatments. 
Previous findings suggested a stronger efficacy of antiglucocorticoids in psychotic depressed subjects 
possibly related to a more pronounced HPA axis dysregulation (Schatzberg 2015). Indeed, our results 
show a tendency toward a greater efficacy of antiglucocorticoid treatments in patients with higher 
baseline cortisol levels and PMD subjects tend to have higher cortisol levels compared with non-
psychotic depressed patients (Nelson and Davis, 1997). However, we did not find a significant effect 
of baseline cortisol levels in the efficacy of GR antagonist in PMD and BD subjects, as responders and 
non-responders had similar baseline cortisol levels. This may be partly due to the fact that previous 
literature tends to support the efficacy of mifepristone in improving psychotic rather than depressive 
symptoms on which our meta-analysis focused (Blasey et al., 2009). However, the mechanism 
associated with clinical improvement of psychotic symptoms after treatment with GR antagonists still 
remains unclear. Zhang and colleagues have investigated the mechanism of mifepristone in rats (Zhang 
et al., 2018) and they have shown that this treatment reduces depression-like behaviours induced by 
chronic IL-1β administration and the effect of IL-1β on corticosterone. Therefore, it is possible to 
hypothesize that mifepristone may have greater efficacy in patients presenting with high levels of 
inflammation rather than (or in addition to) high levels of cortisol. 
 
One main limitation of our meta-analysis stems from the differences between methods of cortisol data 
collection across the studies. For example, two studies (Jahn et al., 2004; O’Dwyer et al., 1995) focused 
on morning blood collection, three studies (Belanoff et al., 2002; Wolkowitz et al., 1999; Young et al., 
2004) focused on afternoon blood collection, one study (Flores et al., 2006) analysed blood collected 
between 6 pm and 1 am, and two of them focused on saliva collection in the evening (McAllister-
Williams et al., 2016; Watson et al., 2012). Salivary cortisol is a valid measure for free cortisol when 
protein binding is an issue in serum (El-Farhan et al., 2016). Moreover, Bozovic and colleagues (2013) 
suggest salivary cortisol as more feasible approach to study HPA axis in research studies due to its ease 
of collection. However, possible confounding effects due to the subject’s habits (e.g. time of food 
intake, smoking, etc.), may influence the results. Therefore, future studies may need to focus on the use 
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of salivary cortisol levels not only because the sampling would be less invasive but also because the 
data may be more informative.  
 
In conclusion, we report the first evidence of a role of baseline cortisol levels in the efficacy 
of antiglucocorticoid treatments in patients with mood disorders. Specifically, our results show a 
significant effect of baseline cortisol levels in predicting the clinical response to cortisol synthesis 
inhibitors (ketoconazole and metyrapone) in the MDD population. Our findings support the possibility 
of tailored and individualised treatment for patients with mood disorders when using antiglucocorticoid 
treatments by implementing stratification of patients on the basis of baseline cortisol levels. Looking to 
the future, this stratification could help us to identify which subgroups could have the greatest benefit 
from cortisol synthesis inhibitors as an add-on treatment to the common antidepressants. 
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Figure 1. Flowchart of the searching process. 
Figure 2. Antiglucocorticoid treatments in patients with mood disorders. 
Figure 3. Cortisol synthesis inhibitors (Metyrapone, Ketoconazole) in MDD patients. 
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